MYLUNG Consortium Study Protocol 2

Launched by US ONCOLOGY RESEARCH · Nov 30, 2022

Keywords

ClinConnect Summary

Lung cancer remains the most lethal malignancy in men and women in the U.S. Providing high quality management of these patients in the community setting as compared to hospital or academic centers offers the opportunity to reduce cost without sacrificing clinical outcome and simultaneously improving patient convenience and value. Many patients diagnosed with late-stage cancers can benefit from advanced biomarker testing, yet not all eligible patients receive this type of diagnostic testing today.

Within advanced non-small-cell lung cancer (aNSCLC), there are many specific somatic mutations...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer
• • Eligible for systemic therapy based on the treating provider's assessment
• • Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease
• • Subjects may be enrolled within 30 days of initiation of systemic therapy
• • Signed informed consent
• Exclusion Criteria:
• • Stage IA at the time of enrollment
• • Subjects with small cell lung cancer
• • Subjects with Unknown primary tumor origin

Trial Officials